EDBI Logo
|  
Flyout Menu

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase(HDAC) Inhibitor SB939

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)

Related Posts

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure

  • 18 06 2026
  • |
Read More

Meet the cleantech innovators helping cut emissions, recycle water

  • 11 06 2026
  • |
Read More

iCapital strengthens Apac presence as demand for alternatives surges among wealthy investors

  • 10 06 2026
  • |
Read More

Can Southeast Asia claim its place in the AI economy?

  • 04 06 2026
  • |
Read More

AlphaSense nearly doubles valuation to $7.5 billion in new funding round

  • 03 06 2026
  • |
Read More

Startup funding reaches $214m in April to May period

  • 03 06 2026
  • |
Read More

Join our community!

Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.

Subscribe now

Investing in high-growth technologies that shape the future economic pillars of Singapore since 1991.

About EDBI

Team

Portfolio

News and Insights

Careers

Contact Us

Linkedin Youtube

© 2025 EDBI. All rights reserved.

Notice: Unauthorised use of the EDBI name and branding in Japan. EDBI officers will never solicit from the public or offer incentives for participation in our programmes. Report any incident to [email protected] if you are unsure if something is a scam.
Learn more
This is default text for notification bar
Learn more